Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 17/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8583785 | 0.79 | PARP1 (0.49) | PARP1PARP2PARP3 | |
| SCHEMBL4470820 | 0.79 | PDPK1 (0.59) | PARP1PARP2PARP3ALDH1A1 | |
| SCHEMBL30874474 | 0.78 | PARP1 (0.47) | PARP1PARP2PARP3 | |
| SCHEMBL23874527 | 0.75 | AURKA (0.43) | NPC1RAB9APARP1PARP2PARP3 | |
| SCHEMBL17646416 | 0.74 | PARP1 (0.37) | NPC1RAB9APARP1PARP2PARP3 | |
| SCHEMBL23478496 | 0.73 | LMNA (0.61) | UBE2TASIC3NPC1RAB9AMEN1 | |
| SCHEMBL23874471 | 0.73 | ASIC3 (0.53) | UBE2TASIC3MEN1ALDH1A1HPGD | |
| SCHEMBL21954228 | 0.73 | SMN1; SMN2 (0.61) | UBE2TASIC3NPC1RAB9AMEN1 | |
| SCHEMBL5973543 | 0.73 | ALDH1A1 (0.61) | UBE2TASIC3MEN1ALDH1A1HPGD | |
| SCHEMBL29049097 | 0.72 | NPC1 (0.44) | NPC1RAB9APARP1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-113166084-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4125883-A1 | COMBINATION THERAPY | Antabio SAS (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2022-04-14 | — | — | US | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| CN-113166084-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ARG1, ELANE, INSR | UBE2T 1024/4885ASIC3 1279/4885NPC1 782/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | UBE2T 2566/4885ASIC3 420/4885NPC1 81/4885 |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | UBE2T 956/4885ASIC3 1267/4885NPC1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.